These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

336 related items for PubMed ID: 36110863

  • 21. Two cases with autoantibodies to small ubiquitin-like modifier activating enzyme: A potential unique subset of dermatomyositis-associated interstitial lung disease.
    Gono T, Tanino Y, Nishikawa A, Kawamata T, Hirai K, Okazaki Y, Shibata Y, Kuwana M.
    Int J Rheum Dis; 2019 Aug; 22(8):1582-1586. PubMed ID: 31050194
    [Abstract] [Full Text] [Related]

  • 22. Clinical evaluation of anti-aminoacyl tRNA synthetase antibodies in Japanese patients with dermatomyositis.
    Matsushita T, Hasegawa M, Fujimoto M, Hamaguchi Y, Komura K, Hirano T, Horikawa M, Kondo M, Orito H, Kaji K, Saito Y, Matsushita Y, Kawara S, Yasui M, Seishima M, Ozaki S, Kuwana M, Ogawa F, Sato S, Takehara K.
    J Rheumatol; 2007 May; 34(5):1012-8. PubMed ID: 17309126
    [Abstract] [Full Text] [Related]

  • 23. Efficacy of Glucocorticoids and Calcineurin Inhibitors for Anti-aminoacyl-tRNA Synthetase Antibody-positive Polymyositis/dermatomyositis-associated Interstitial Lung Disease: A Propensity Score-matched Analysis.
    Hozumi H, Fujisawa T, Nakashima R, Yasui H, Suzuki Y, Kono M, Karayama M, Furuhashi K, Enomoto N, Inui N, Nakamura Y, Mimori T, Suda T.
    J Rheumatol; 2019 May; 46(5):509-517. PubMed ID: 30647164
    [Abstract] [Full Text] [Related]

  • 24. Comparison of anti-aminoacyl-tRNA synthetase antibody-related and idiopathic non-specific interstitial pneumonia.
    Shioya S, Masuda T, Yamaguchi K, Sakamoto S, Horimasu Y, Nakashima T, Miyamoto S, Senoo T, Iwamoto H, Ohshimo S, Fujitaka K, Hamada H, Hattori N.
    Respir Med; 2019 Jun; 152():44-50. PubMed ID: 31128609
    [Abstract] [Full Text] [Related]

  • 25. Anti-aminoacyl-tRNA synthetase antibodies in clinical course prediction of interstitial lung disease complicated with idiopathic inflammatory myopathies.
    Yoshifuji H, Fujii T, Kobayashi S, Imura Y, Fujita Y, Kawabata D, Usui T, Tanaka M, Nagai S, Umehara H, Mimori T.
    Autoimmunity; 2006 May; 39(3):233-41. PubMed ID: 16769657
    [Abstract] [Full Text] [Related]

  • 26. Dermatomyositis with Rapidly Progressive Interstitial Lung Disease Treated with Rituximab: A Report of 3 Cases in Japan.
    Tokunaga K, Hagino N.
    Intern Med; 2017 May; 56(11):1399-1403. PubMed ID: 28566605
    [Abstract] [Full Text] [Related]

  • 27. Peripheral lymphocyte count defines the clinical phenotypes and prognosis in patients with anti-MDA5-positive dermatomyositis.
    Jin Q, Fu L, Yang H, Chen X, Lin S, Huang Z, Gao B, Tian X, Jiang W, Shu X, Lu X, Wang G, Peng Q.
    J Intern Med; 2023 Apr; 293(4):494-507. PubMed ID: 36682032
    [Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29. The relationship between type 1 IFN and vasculopathy in anti-MDA5 antibody-positive dermatomyositis patients.
    Ono N, Kai K, Maruyama A, Sakai M, Sadanaga Y, Koarada S, Inoue T, Tada Y.
    Rheumatology (Oxford); 2019 May 01; 58(5):786-791. PubMed ID: 30541137
    [Abstract] [Full Text] [Related]

  • 30. Clinical manifestation and prognostic factor in anti-melanoma differentiation-associated gene 5 antibody-associated interstitial lung disease as a complication of dermatomyositis.
    Gono T, Kawaguchi Y, Satoh T, Kuwana M, Katsumata Y, Takagi K, Masuda I, Tochimoto A, Baba S, Okamoto Y, Ota Y, Yamanaka H.
    Rheumatology (Oxford); 2010 Sep 01; 49(9):1713-9. PubMed ID: 20498012
    [Abstract] [Full Text] [Related]

  • 31. Interstitial lung disease associated with anti-PM/Scl or anti-aminoacyl-tRNA synthetase autoantibodies: a similar condition?
    Lega JC, Cottin V, Fabien N, Thivolet-Béjui F, Cordier JF.
    J Rheumatol; 2010 May 01; 37(5):1000-9. PubMed ID: 20231208
    [Abstract] [Full Text] [Related]

  • 32. Novel endotypes of antisynthetase syndrome identified independent of anti-aminoacyl transfer RNA synthetase antibody specificity that improve prognostic stratification.
    Wu S, Xiao X, Zhang Y, Zhang X, Wang G, Peng Q.
    Ann Rheum Dis; 2024 May 15; 83(6):775-786. PubMed ID: 38395605
    [Abstract] [Full Text] [Related]

  • 33. Clinical Significance of Serum Chitotriosidase Level in Anti-MDA5 Antibody-positive Dermatomyositis-associated Interstitial Lung Disease.
    Fujisawa T, Hozumi H, Yasui H, Suzuki Y, Karayama M, Furuhashi K, Enomoto N, Nakamura Y, Inui N, Suda T.
    J Rheumatol; 2019 Aug 15; 46(8):935-942. PubMed ID: 31092718
    [Abstract] [Full Text] [Related]

  • 34. Clinical subsets associated with different anti-aminoacyl transfer RNA synthetase antibodies and their association with coexisting anti-Ro52.
    Yamasaki Y, Satoh M, Mizushima M, Okazaki T, Nagafuchi H, Ooka S, Shibata T, Nakano H, Ogawa H, Azuma K, Maeda A, Tonooka K, Ito H, Takakuwa Y, Inoue M, Mitomi H, Kiyokawa T, Tsuchida K, Matsushita H, Mikage H, Murakami Y, Chan JY, Ozaki S, Yamada H.
    Mod Rheumatol; 2016 Aug 15; 26(3):403-9. PubMed ID: 26344678
    [Abstract] [Full Text] [Related]

  • 35. Different Multivariable Risk Factors for Rapid Progressive Interstitial Lung Disease in Anti-MDA5 Positive Dermatomyositis and Anti-Synthetase Syndrome.
    Zuo Y, Ye L, Chen F, Shen Y, Lu X, Wang G, Shu X.
    Front Immunol; 2022 Aug 15; 13():845988. PubMed ID: 35320936
    [Abstract] [Full Text] [Related]

  • 36. Age distribution and prevalence in different age groups of four myositis-specific autoantibodies, including anti-ARS, anti-MDA5, anti-Mi-2, and anti-TIF1γ antibodies.
    Ueda-Hayakawa I, Tonomura K, Maekawa A, Kaneda E, Arase N, Fujimoto M.
    J Dermatol; 2023 Aug 15; 50(8):1058-1062. PubMed ID: 36890683
    [Abstract] [Full Text] [Related]

  • 37. The comparison of nailfold videocapillaroscopy findings between anti-melanoma differentiation-associated gene 5 antibody and anti-aminoacyl tRNA synthetase antibody in patients with dermatomyositis complicated by interstitial lung disease.
    Wakura R, Matsuda S, Kotani T, Shoda T, Takeuchi T.
    Sci Rep; 2020 Sep 24; 10(1):15692. PubMed ID: 32973255
    [Abstract] [Full Text] [Related]

  • 38. Anti-MDA5 autoantibodies associated with juvenile dermatomyositis constitute a distinct phenotype in North America.
    Mamyrova G, Kishi T, Shi M, Targoff IN, Huber AM, Curiel RV, Miller FW, Rider LG, Childhood Myositis Heterogeneity Collaborative Study Group.
    Rheumatology (Oxford); 2021 Apr 06; 60(4):1839-1849. PubMed ID: 33140079
    [Abstract] [Full Text] [Related]

  • 39. Clinical characteristics and prognostic analysis of idiopathic inflammatory myopathy with positive anti-aminoacyl-tRNA synthetase antibodies: A single center experience.
    Zhang D, Wang H, Zhou X, Yang J, Liu Y, Wang W, Jiang P, Fan B.
    Immun Inflamm Dis; 2023 Nov 06; 11(11):e1085. PubMed ID: 38018600
    [Abstract] [Full Text] [Related]

  • 40. Clinical significance of myositis-specific autoantibody profiles in Japanese patients with polymyositis/dermatomyositis.
    Temmoku J, Sato S, Fujita Y, Asano T, Suzuki E, Kanno T, Furuya MY, Matsuoka N, Kobayashi H, Watanabe H, Koga T, Shimizu T, Kawakami A, Migita K.
    Medicine (Baltimore); 2019 May 06; 98(20):e15578. PubMed ID: 31096460
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 17.